
Please try another search
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Douglas Edward Williams | 67 | 2024 | Chair of Board |
Andrew Levin | 48 | 2018 | Director |
Judith A. Dunn | 62 | 2021 | Independent Director |
Kimberlee Cobleigh Drapkin | 57 | 2025 | Independent Director |
Alexander G. Cumbo | 54 | 2025 | Independent Director |
Stephen Basil Thomas | 36 | 2024 | Director |
Aoife M. Brennan | 49 | 2024 | Interim Principal Financial Officer, CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review